Mizoribine and mycophenolate mofetil.

Area of Science:

• Immunology
• Pharmacology
• Transplantation Medicine

Background:

• Mizoribine (MZR) and mycophenolate mofetil (MMF) are immunosuppressive drugs targeting lymphocyte proliferation via IMPDH inhibition.
• MZR, a nucleoside, and MMF, a mycophenolic acid prodrug, offer distinct mechanisms for immune modulation.
• Both agents have demonstrated clinical utility in preventing transplant rejection and treating autoimmune conditions.

Purpose of the Study:

• To compare the mechanisms and applications of mizoribine (MZR) and mycophenolate mofetil (MMF) as immunosuppressive agents.
• To highlight their selective inhibition of lymphocyte proliferation through IMPDH antagonism.
• To review their therapeutic uses and safety profiles in transplantation and autoimmune diseases.

Main Methods:

• Review of literature on MZR and MMF, focusing on their biochemical mechanisms of action.
• Analysis of preclinical and clinical data regarding efficacy and safety in immunosuppression.
• Examination of their regulatory approvals and therapeutic indications.

Main Results:

• MZR and MMF selectively inhibit lymphocyte proliferation by blocking IMPDH, a key enzyme in purine synthesis.
• MZR demonstrates low oncogenicity and a low incidence of severe adverse reactions.
• MMF, as a prodrug of mycophenolic acid, enhances oral bioavailability and has FDA approval for renal transplant rejection prevention.

Conclusions:

• MZR and MMF are effective immunosuppressants with distinct origins and properties.
• Their selective action on IMPDH offers therapeutic benefits in organ transplantation and autoimmune diseases.
• Favorable safety profiles support their continued use in clinical practice.